Core Viewpoint - The company successfully acquired the land use rights for a plot in Shenzhen for RMB 60.4 million, which aligns with its strategic plan to develop an intelligent industrial base [1][2]. Group 1: Land Acquisition Details - The company participated in the bidding for the land use rights of plot A628-0045, which was publicly announced by the Shenzhen Municipal Government [1]. - The land area is 69,986.43 square meters, with a usage period of 30 years [1]. - The land is categorized under the encouraged industry category for "new drug development and industrialization" as per the "Industrial Structure Adjustment Guidance Catalog (2024)" [1]. Group 2: Purpose and Impact of the Acquisition - The purpose of acquiring the land is to meet the needs of the company's intelligent industrial base project, which is in line with its development strategy and aims for high-quality growth [2]. - The funding for the land acquisition comes from the company's own or self-raised funds, ensuring no adverse impact on its main business or financial stability [2]. - Once the new industrial base is operational, the company plans to relocate its operations and will cooperate with local government authorities to vacate the current facility [2].

Major Events - Robotech plans to issue H-shares and list on the Hong Kong Stock Exchange [1] - Leo Group plans to issue H-shares and list on the Hong Kong Stock Exchange [1] Performance - Tianji shares gain high market attention for solid-state battery concept; subsidiary has obtained patents for lithium sulfide materials and their preparation methods [1][1] - Weiguang Bio has successfully acquired land use rights and signed a transaction confirmation [1] - Gansu Energy's Changle Company has officially put the 5th unit of the 2×1000 MW coal-fired unit expansion project into commercial operation [1] - Zhaoxin shares' largest shareholder did not trade company stocks during abnormal trading fluctuations [1] - Electric Alloy's shareholder plans to acquire indirect shares through block trading, involving no more than 2.4 million shares [1] - Nanchin Technology plans to issue convertible bonds to raise no more than 1.933 billion yuan for research and industrialization of power management chips in the intelligent computing field [1] - Ningbo Ocean plans to invest in the establishment of two overseas companies [1] - Jidian shares received 913 million yuan in national renewable energy subsidy funds in August [1] - Shennong Group sold 166,400 pigs in August, generating sales revenue of 285 million yuan [1] - Tianbang Food sold 529,700 commercial pigs in August, with sales revenue of 621 million yuan [1]

智通财经APP讯，卫光生物(002880.SZ)公告，公司于2025年9月5日参加深圳交易集团有限公司土地矿业 权业务分公司举办的光明区马田街道宗地号为A628-0045的国有建设用地使用权挂牌出让活动，以6040 万元的价格成功竞得上述地块的使用权，并签署了《成交确认书》。该土地用途为普通工业用地，土地 面积69,986.43平方米。 （原标题：卫光生物(002880.SZ)以6040万元竞得一处光明区工业用地） ...

卫光生物（002880）(002880.SZ)公告，公司于2025年9月5日参加深圳交易集团有限公司土地矿业权业 务分公司举办的光明区马田街道宗地号为A628-0045的国有建设用地使用权挂牌出让活动，以6040万元 的价格成功竞得上述地块的使用权，并签署了《成交确认书》。该土地用途为普通工业用地，土地面积 69,986.43平方米。 ...

证券代码:002880 证券简称:卫光生物 公告编号:2025-043 深圳市卫光生物制品股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 深圳市卫光生物制品股份有限公司（以下简称公司）于2025年8月15日召开 第四届董事会第二次会议，审议通过了《关于拟参与竞拍国有建设用地使用权的 议案》，同意公司参与竞拍深圳市国有建设用地使用权出让公告（深土交告〔2025〕 的光明区马田街道宗地号为A628-0045的国有建设用地使用权挂牌出让活动，以 人民币60,400,000元（陆仟零肆拾万元）的价格成功竞得上述地块的使用权，并 签署了《成交确认书》（深土交成〔2025〕29号）。 公司本次参与竞得土地使用权事项的资金来源为自有资金或自筹资金，不构 成关联交易，也不构成《上市公司重大资产重组管理办法》规定的重大资产重组。 现将有关情况公告如下： 第十三条"医药"的第 2 项"新药开发与产业化：拥有自主知识产权的创新药和改 良型新药、儿童药、短缺药、罕见病用药，重大疾病防治疫苗、新型抗体药物、 重组蛋白质药物、核酸药物、生物酶制剂、基因治疗和细胞治疗药物" ...

Group 1 - The company, Weiguang Biological (002880.SZ), successfully acquired the land use rights for a state-owned construction land in Guangming District, Shenzhen, for RMB 60.4 million [1] - The funding for this land acquisition will come from the company's own funds or self-raised funds [1] - After the completion of the intelligent industry base, the company plans to relocate its operations to the new site and will cooperate with the relevant government departments to complete the recovery of the existing factory area [1]

Group 1 - The company, Weiguang Biological (002880), successfully acquired the land use rights for a state-owned construction land in Guangming District, Shenzhen, for a price of 60.4 million RMB [1] - The acquisition took place during a public bidding event organized by Shenzhen Trading Group Co., Ltd. on September 5 [1] - The company has signed a "Transaction Confirmation" document following the successful bid [1]

公司本次参与竞得土地使用权事项的资金来源为自有资金或自筹资金，不构 成关联交易，也不构成《上市公司重大资产重组管理办法》规定的重大资产重组。 现将有关情况公告如下： 一、地块的基本情况 （一）宗地代码：440311201007GB00106 （二）宗地号：A628-0045 （三）土地位置：光明区马田街道 证券代码:002880 证券简称:卫光生物 公告编号:2025-043 深圳市卫光生物制品股份有限公司 关于竞得土地使用权并签署成交确认书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 深圳市卫光生物制品股份有限公司（以下简称公司）于2025年8月15日召开 第四届董事会第二次会议，审议通过了《关于拟参与竞拍国有建设用地使用权的 议案》，同意公司参与竞拍深圳市国有建设用地使用权出让公告（深土交告〔2025〕 28号）公示的A628-0045宗地使用权。 2025年9月5日，公司参加深圳交易集团有限公司土地矿业权业务分公司举办 的光明区马田街道宗地号为A628-0045的国有建设用地使用权挂牌出让活动，以 人民币60,400,000元（陆仟零肆拾万元） ...

Core Viewpoint - The blood products industry is experiencing significant performance differentiation among listed companies due to fluctuating terminal medical demand, ongoing centralized procurement policies, and intensified competition for plasma station resources [1][2]. Revenue Performance - The blood products industry has shown a clear tiered revenue structure, with leading companies benefiting from resource barriers while smaller firms struggle with revenue growth [2][3]. - Shanghai Raist achieved a revenue of 3.952 billion yuan, with a year-on-year plasma collection increase of nearly 12% [2]. - Tian Tan Bio reported a revenue of 3.110 billion yuan, a year-on-year increase of 9.47%, supported by its stable plasma collection capabilities [2]. - Hualan Bio generated a revenue of 1.798 billion yuan, up 8.8% year-on-year, with its blood products segment contributing 1.737 billion yuan, a 7.57% increase [2]. - The top three companies accounted for 74.64% of the total revenue of the eight listed companies in the industry [2]. Profitability Analysis - There is a significant disparity in net profit performance, with only two companies reporting positive year-on-year growth in net profit [4][5]. - Shanghai Raist led with a net profit of 1.03 billion yuan, while Hualan Bio saw a notable increase of 17.19% in net profit to 516 million yuan, driven by improved gross margins [4]. - Tian Tan Bio's net profit decreased by 12.88% to 633 million yuan, impacted by declining product sales prices and reduced interest income [4]. - The profitability of smaller companies is under pressure, with Baiya Bio reporting a net profit of 225 million yuan and a cash dividend plan reflecting shareholder returns [5]. - Bai Lin Bio's net profit fell by 27.89% to 236 million yuan due to capacity expansion efforts, while Wei Guang Bio's net profit slightly decreased by 2.02% to 108 million yuan [5][6]. Industry Challenges - The industry faces challenges such as weak terminal demand, ongoing centralized procurement pressures, and financial and R&D constraints [6]. - The demand for conventional products like human albumin has decreased due to adjustments in treatment rhythms at medical institutions [6]. - Centralized procurement policies continue to exert pressure on pricing, affecting revenue from related business lines [6]. - Companies are experiencing tight funding issues as they invest in expanding plasma stations and advancing new product development [6].

Core Viewpoint - The company, Weigao Biologics, reported stable financial performance in the first half of 2025 despite a decline in demand and prices in the blood products industry, achieving revenue of 518 million yuan and a net profit of 108 million yuan, maintaining profitability amidst industry challenges [1] Group 1: Financial Performance - In the first half of 2025, Weigao Biologics achieved operating revenue of 518 million yuan and a net profit attributable to shareholders of 108 million yuan, with a non-recurring net profit of 106 million yuan, showing stability compared to the same period last year [1] - The company has become one of the few publicly listed companies in the blood products sector to maintain steady profits amid declining industry demand and prices [1] Group 2: Industry Position and Expansion Plans - The blood products industry is undergoing significant consolidation, with state-owned enterprises projected to account for 36% of national production capacity and 39% of plasma collection by 2024 [1] - Weigao Biologics announced plans for a private placement to raise up to 1.5 billion yuan, with 1.2 billion yuan allocated to an intelligent industrial base project aimed at doubling its plasma processing capacity from 650 tons to 1200 tons annually [2] - The intelligent factory will produce various blood products, helping to alleviate supply-demand imbalances and enhance the company's market share and industry standing [2] Group 3: Research and Development - The company has increased its R&D investment by 14% year-on-year, reaching 23.83 million yuan, focusing on addressing low plasma utilization and limited product variety in the domestic market [4] - Weigao Biologics has successfully launched 11 products across 23 specifications, positioning itself among the top players in the national blood products industry [3] Group 4: Innovation and New Product Development - The company is advancing the industrialization of new products, including the fourth-generation intravenous immunoglobulin and human fibrinogen adhesive, with ongoing clinical trials and regulatory processes [4] - The company emphasizes innovation as a key driver for development, aiming to transition from scale expansion to quality and efficiency improvements in the blood products sector [4] Group 5: Real Estate and Ecosystem Development - Weigao Biologics' property rental income increased by 28% to 73.67 million yuan in the first half of 2025, with an occupancy rate of approximately 80% in its life sciences park [7] - The Weigao Life Science Park has attracted over 60 enterprises and has been recognized as an exemplary case in the biopharmaceutical industry, enhancing the company's ecosystem and regional economic development [7][8] - The company has established three specialized industrial funds to invest in high-quality projects in biomedicine and medical devices, fostering synergy with its core business [8]